Kabra Drugs Limited
BBSE:KABRADG16.64
INR
-0.12
(-0.72%)
ISIN
INE323K01017
Return %
Stock
S&P 500
1Y
-16.30
14.20
3Y
166.24
81.12
5Y
191.93
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- Chennai India
- IPO Date
- Mar 3, 1993
- Website
- kabradrugs.com
- Similar Companies
- Business
- Kabra Drugs Limited is an India-based pharmaceutical company engaged in the development, manufacturing, marketing, and contract production of a diverse range of finished dosage formulations and generic pharmaceutical products. Founded in 1989 and headquartered in Indore, Madhya Pradesh, India, the company operates within the formulation and generic drug manufacturing segment of the healthcare industry, trading publicly on the BSE under the ticker symbol KABRADG. The company operates dedicated manufacturing facilities capable of producing multiple pharmaceutical dosage forms, catering to various therapeutic categories including analgesics, antipyretics, anti-inflammatory agents, antibiotics, antibacterials, cardiovascular treatments, gastrointestinal agents, respiratory formulations, antidiabetics, and nutritional supplements. Its comprehensive product portfolio comprises oral solid dosages, such as uncoated, film-coated, and enteric-coated tablets; oral solid capsules, encompassing hard gelatin capsules and extended-release pellet formulations; liquid orals, including therapeutic syrups, oral suspensions, drops, and digestive enzyme solutions; dry syrups and oral reconstitutable powders, specifically formulated for pediatric anti-infective applications; small-volume parenterals, including sterile liquid injectables and dry powder injectable vials; and topical formulations, including external ointments, creams, and dermatological gels. In addition to marketing proprietary branded and generic formulations, Kabra Drugs Limited provides extensive contract manufacturing, third-party manufacturing, and loan licensing services to domestic pharmaceutical marketers, institutional distributors, and healthcare organizations. Kabra Drugs Limited primarily distributes its pharmaceutical products across domestic regional markets throughout India, serving retail pharmacy networks, independent distributors, hospital chains, and public healthcare tenders. In recent operational developments, Kabra Drugs Limited has focused on upgrading its manufacturing infrastructure to ensure ongoing alignment with revised Schedule M and current Good Manufacturing Practice (cGMP) standards, enhancing batch tracking, validation protocols, and analytical quality control systems. To expand its revenue streams and optimize production capacity utilization, the company has actively pursued strategic third-party contract manufacturing tie-ups and expanded its supply relationships with regional healthcare distributors and institutional buyers. Additionally, Kabra Drugs Limited has implemented operational efficiency measures aimed at streamlining procurement, improving working capital management, and restructuring its distribution logistics to strengthen its market position within the competitive Indian generic formulation sector.